Results 61 to 70 of about 8,627 (176)

Design and rationale of dabigatran's stroke prevention in real life in Turkey (D-SPIRIT)

Türk Kardiyoloji Derneği Arşivi, 2016
Objective: The D-SPIRIT registry is designed to investigate the safety and efficacy of dabigatran etexilate in patients with nonvalvular atrial fibrillation (NVAF) and to collect data on outcomes in clinical practice.
Uğur Önsel Türk, Emin Alioğlu, Eşref Tunçer, Mehmet Emre Özpelit, Nihat Pekel, İstemihan Tengiz, Nurullah Çetin, Onur Dalgıç, Caner Topaloğlu, Nazile Bilgin, Cihan Altın, Tolga Özdemirkıran, Kamil Tülüce, Ebru İpek Türkoğlu, Ebru Özpelit   +14 more
doaj   +1 more source

Spinal subarachnoid and subdural hematoma presenting as a Brown-Séquard-like myelopathy following minor trauma in a patient on dabigatran etexilate

Radiology Case Reports, 2017
Dabigatran etexilate is a relatively new anticoagulant from the class of direct thrombin inhibitors which is administered orally and does not require routine blood work monitoring.
Allen R. Wolfe, MD, MPH, Raihan M. Faroqui, BA, George A. Visvikis, MD, Michael T. Mantello, MD, Allan B. Perel, MD, Sanjit O. Tewari, MD   +5 more
doaj   +1 more source

Hemopericardium and cardiac tamponade in a patient treated with dabigatran etexilate [PDF]

, 2016
WOS: 000368568400013PubMed ID: 26798391Dabigatran etexilate is one of the new oral anticoagulants approved to reduce the risk of stroke in patients with atrial fibrillation (AF). A variety of bleeding complications with dabigatran have been reported, but
Kızılırmak, Filiz, Canpolat, Habibe Gamze, Demir, Gültekin Günhan, Karaca, Oğuz, Güneş, Hacı Murat, Güler, Ekrem   +5 more
core   +1 more source

Transforming Treatment: The Impact of Bariatric Surgery on Oral Drug Absorption

Obesity Reviews, Volume 27, Issue 4, April 2026.
ABSTRACT Obesity represents a significant threat to global public health, with an estimated 16% of adults worldwide (2022) being classified as people with obesity, with a body mass index of 30 or more. Bariatric surgery is regarded as the most effective treatment option for people with obesity, with the three main types of bariatric surgery being ...
Danielle Wigg, Andrea Edginton, Matthew D. Jones, Nikoletta Fotaki   +3 more
wiley   +1 more source

Adjusting the Preincubation Conditions to Enhance the Ames Test for Detecting the Mutagenicity of N‐Nitrosamines

Environmental and Molecular Mutagenesis, Volume 67, Issue 3, March 2026.
ABSTRACT Conducting S9‐mediated preincubations at slightly acid pHs (e.g., pH 5.0 to pH 6.5) has been reported to enhance the mutagenicity of small‐molecule nitrosamines in the Ames test. In this study, we have evaluated the effect of adjusting the preincubation mix used in the Enhanced Ames Test (EAT) from pH 7.4 to pH 6.0 and supplying the activation
Michelle E. Bishop, Audrey M. Sims, Sharon K. Guerrero, Kamela Mitchell, Nan Mei, Hannah Xu, Naomi L. Kruhlak, Sruthi T. King, Robert T. Dorsam, Aisar H. Atrakchi, Timothy J. McGovern, Robert H. Heflich   +11 more
wiley   +1 more source

Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab—A Case Report

, 2017
Introduction Idarucizumab is a reversal agent for dabigatran etexilate. By reversing the anticoagulating effect of dabigatran etexilate with idarucizumab (Praxbind), patients presenting with an acute ischemic stroke can now be eligible for thrombolysis ...
Tireli, Derya, Nordling, Mette Maria, Mette Maria Nordling, Jun He, Troels Wienecke, Wienecke, Troels, He, Jun, Derya Tireli   +7 more
core   +1 more source

Clinical Evaluation of Drug–Drug Interactions With Aficamten

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Aficamten is a next‐in‐class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). A comprehensive drug–drug interaction (DDI) evaluation of aficamten was achieved through two phase 1 studies in ...
Neha Maharao, Donghong Xu, Punag Divanji, Tyrell J. Simkins, Jianlin Li, Camelia Dumitrescu, Priyanka Solanki, Adrienne Griffith, Stephen B. Heitner, Stuart Kupfer, Polina German, Justin D. Lutz   +11 more
wiley   +1 more source

UV SPECTROPHOTOMETRIC ASSAY METHOD DEVELOPMENT AND VALIDATION OF DABIGATRAN ETEXILATE IN CAPSULES [PDF]

, 2015
Objective: To develop a simple and a cheap UV spectrophotometric method for the quantitative estimation of Dabigatran etexilate in capsules and validate as per ICH guidelines.Methods: The optimized method uses triethyl ammonium phosphate aqueous solution
Kumar, A. Ashok, Bhavani, G., Hussain, Syed Shahed   +2 more
core   +1 more source

Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the netherlands [PDF]

, 2012
OBJECTIVES: Dabigatran etexilate is a new oral direct thrombin inhibitor for prophylaxis of venous thromboembolism (VTE) in patients who have elective surgery for total hip replacement (THR) or total knee replacement (TKR).
Kappelhoff, B.S., Brouwers, J.R., Postma, M.J.; id_orcid, van Hulst, M.; id_orcid   +3 more
core   +5 more sources

Dicloxacillin and Flucloxacillin Inhibit Hepatic Uptake Transporters—In Vitro Investigations and Physiologically Based Pharmacokinetic Modeling

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Dicloxacillin and flucloxacillin are β‐lactamase‐resistant penicillin antibiotics that have been in clinical use for over 50 years. While both antibiotics are known to induce cytochrome P450 enzymes, there is limited information available regarding their interactions with drug transporters.
Noora Sjöstedt, Ogochukwu U. Amaeze, Jeroen J. M. W. van den Heuvel, Tore B. Stage, Jan B. Koenderink, Nina Isoherranen, Heidi Kidron, Erkka Järvinen   +7 more
wiley   +1 more source